Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations
- 1 September 2017
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16 (5) , 600-606
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation Therapeutics (SANDERS14A0, HELTSH13A1, GOSS13A0, FLUME13A1, CLANCY09Y0, SORSCH15RO, ORENST14Y0, NICKR0, DAINES14Y0)
- National Institutes of Health (KL2 TR000428, P30 DK089507)
- University of Wisconsin-Madison ICTR (NIH UL1 TR000427)
- South Carolina Clinical & Translational Research (SCTR) Institute (UL1TR001450)
This publication has 22 references indexed in Scilit:
- Risk factors for rate of decline in FEV1 in adults with cystic fibrosisJournal of Cystic Fibrosis, 2012
- Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosisPediatric Pulmonology, 2012
- Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosisThorax, 2011
- Approach to treating cystic fibrosis pulmonary exacerbations varies widely across us CF care centersPediatric Pulmonology, 2011
- Location and Duration of Treatment of Cystic Fibrosis Respiratory Exacerbations Do Not Affect OutcomesAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosisPediatric Pulmonology, 2010
- Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbationsRespiratory Research, 2010
- Return of FEV1 after pulmonary exacerbation in children with cystic fibrosisPediatric Pulmonology, 2010
- Patient-reported respiratory symptoms in cystic fibrosisJournal of Cystic Fibrosis, 2009
- Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosisPediatric Pulmonology, 2002